In March 2003, 3-Dimensional Pharmaceuticals (Nasdaq: DDDP) was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals , Inc. (3dp.com) had been a drug discovery company using DiscoverWorks(TM), a proprietary technology platform, to reduce the cost and improve the quality of drugs entering clinical trials. DiscoverWorks(TM) uniquely integrated high-throughput screening, combinatorial chemistry and structure-based drug design for efficient drug discovery using targets from genome sequencing. 3DP used DiscoverWorks(TM) in its own drug discovery programs and to provide discovery services to pharmaceutical and agrochemical partners. The company's internal research programs were focused on the discovery of orally active small-molecule pharmaceuticals for the treatment of cardiovascular disease and cancer
